Primary Sjogren's syndrome: central and peripheral nervous system involvements

被引:3
作者
Mekinian, A. [1 ]
Tennenbaum, J. [1 ]
Lahuna, C. [1 ]
Dellal, A. [2 ]
Belfeki, N. [3 ]
Capron, J. [4 ]
Januel, E. [4 ]
Stankoff, B. [4 ]
Alamowitch, S. [4 ]
Fain, O. [1 ]
机构
[1] Sorbonne Univ, Hop St Antoine, AP HP,Biotherapy Dept DMU i3, Serv Med Interne & Inflammat Immunopathol, Paris, France
[2] Hop Montfermeil, Serv Med Interne & Rhumatol, Montfermeil, France
[3] Hop Melun, Serv Med Interne, Melun, France
[4] Sorbonne Univ, Hop St Antoine, AP HP, Serv Neurol, Paris, France
关键词
Sjogren's syndrome; neurological involvement; outcome; treatment; INTRAVENOUS IMMUNOGLOBULIN THERAPY; MANIFESTATIONS; SPECTRUM; NEURONOPATHY; HEMORRHAGE; RITUXIMAB; EFFICACY; OUTCOMES; PATIENT; IVIG;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Primary Sjogren's syndrome (pSS) is a common systemic autoimmune disease characterised by exocrinopathy resulting in dryness of the mouth and eyes, unexplained fatigue and diffuse pain. Neurological involvement is uncommon in pSS, involving the central nervous system in 2-5% of cases and more frequently the peripheral nervous system in 5-15% of cases. The diagnosis of pSS is to be considered when confronted with symptoms such as mouth and eye dryness, fatigue and pain, the most frequent of pSS symptoms. Objective measures of oral and eye dryness may help assert the diagnosis of pSS, as well as ACR/EULAR criteria. Differential diagnoses have to be excluded in patients exhibiting neurological symptoms, such as cryoglobulinaemic vasculitis or multiple sclerosis, before considering a neurological involvement specific to pSS. The treatment of these neurological manifestations takes into account different parameters, such as the presence of cryoglobulinaemic vasculitis, the severity of the symptoms, a rapidly progressing evolution and the failure of previous symptomatic treatments.
引用
收藏
页码:S103 / S109
页数:7
相关论文
共 48 条
[1]   White matter abnormalities in primary Sjogren syndrome [J].
Akasbi, M. ;
Berenguer, J. ;
Saiz, A. ;
Brito-Zeron, P. ;
Perez-De-Lis, M. ;
Bove, A. ;
Diaz-Lagares, C. ;
Retamozo, S. ;
Blanco, Y. ;
Perez-Alvarez, R. ;
Bosch, X. ;
Siso, A. ;
Graus, F. ;
Ramos-Casals, M. .
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2012, 105 (05) :433-443
[2]   Epidemiology of neurological manifestations in Sjogren's syndrome: data from the French ASSESS Cohort [J].
Alegria, Guillermo Carvajal ;
Guellec, Dewi ;
Mariette, Xavier ;
Gottenberg, Jacques-Eric ;
Dernis, Emmanuelle ;
Dubost, Jean-Jacques ;
Trouvin, Anne-Priscille ;
Hachulla, Eric ;
Larroche, Claire ;
Le Guern, Veronique ;
Cornec, Divi ;
Devauchelle-Pensec, Valerie ;
Saraux, Alain .
RMD OPEN, 2016, 2 (01)
[3]   NECROTIZING ARTERITIS AND SPINAL SUB-ARACHNOID HEMORRHAGE IN SJOGREN SYNDROME [J].
ALEXANDER, EL ;
CRAFT, C ;
DORSCH, C ;
MOSER, RL ;
PROVOST, TT ;
ALEXANDER, GE .
ANNALS OF NEUROLOGY, 1982, 11 (06) :632-635
[4]  
Alunno A, 2019, CLIN EXP RHEUMATOL, V37, pS192
[5]   Biopsy-Proven Small-Fiber Neuropathy in Primary Sjogren's Syndrome: Neuropathic Pain Characteristics, Autoantibody Findings, and Histopathologic Features [J].
Birnbaum, Julius ;
Lalji, Aliya ;
Saed, Aveen ;
Baer, Alan N. .
ARTHRITIS CARE & RESEARCH, 2019, 71 (07) :936-948
[6]  
Blanc Frederic, 2013, ISRN Neurol, V2013, P501327, DOI 10.1155/2013/501327
[7]  
Coates T, 1999, J RHEUMATOL, V26, P1301
[8]   Intravenous Immunoglobulin and Mycophenolate Mofetil for Long-Standing Sensory Neuronopathy in Sjogren's Syndrome [J].
Danieli, Maria Giovanna ;
Pettinari, Lucia ;
Morariu, Ramona ;
Monteforte, Fernando ;
Logullo, Francesco .
CASE REPORTS IN IMMUNOLOGY, 2012, 2012
[9]  
De Seze J, 2006, J RHEUMATOL, V33, P709
[10]   The prevalence of Sjogren syndrome in patients with primary progressive multiple sclerosis [J].
de Seze, J ;
Devos, D ;
Castelnovo, G ;
Labauge, P ;
Dubucquoi, S ;
Stojkovic, T ;
Ferriby, D ;
Vermersch, P .
NEUROLOGY, 2001, 57 (08) :1359-1363